Annual Genotoxic Impurities Summit
01-02

June 2017

Austria

Vienna

Hotel Am Konzerthaus Vienna MGallery by Sofitel

Am Heumarkt 35-37, 1030

About Summit

This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on the implementation of recent updates to the ICH M7 guidelines in regard to genotoxic impurities. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna this coming June!

Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:

  • Research and Development
  • Drug Development
  • Analitical Science
  • Mass Spectrometry
  • LC-MS
  • Formulation
  • Microscopy
  • GMP
  • Technology transfer
  • Qualty assuarance
  • Quality by Design (QbD)
  • Toxicology
  • Genotoxicology
  • Genotoxic impurities
  • Drug Discovery
  • Drug Design
  • Chromatography
  • Spectroscopy
  • Purification
  • Assay Development
  • Chemistry (analytical, organic, medicinal, protein)
  • Good Laboratory Practice
  • Validation
  • Quality control
  • Regulatory
  • Genotoxin
  • Impurities
Key Practical Learning Points of the Summit

  • Successful step-by-step experience on the implementation of recent updates in ICH M7
  • Regulatory and practical scientific considerations for efficient genotoxic impurity identification and control
Speakers
Dr. Andrew Teasdale

Principle Scientist

AstraZeneca, UK

Dr. Larry Wigman

Principal Scientific Manager (SMACQC)

Genentech, US

Dr. Laura Custer

Head of Genetic Toxicology, Associate Director

Bristol-Myers Squibb, US

Dr. Fenghe Qiu

Senior Research Fellow

Boehringer Ingelheim Pharmaceuticals Inc, US

Dr. Lutz Müller

Project Leader in Pharmaceutical Sciences

F. Hoffmann-La Roche Innovation Center Basel, Switzerland

Dr. Raphael Nudelman

Director, Chemical & Computational Toxicology

Teva Pharmaceutical Industries Ltd., Israel

Dr. Alexander Amberg

Head of In Silico Toxicology

R&D Preclinical Safety FF Sanofi-Aventis Deutschland GmbH, Germany

Dr. Jacques Van Gompel

EU Head Genetic Toxicology Mechanistic & Investigative Toxicology Discovery Sciences

Janssen Pharmaceutica NV, Belgium

Dr. Roustem Saiakhov

President

MultiCASE Incorporated, US

Dr. Catrin Hasselgren

Senior Principal Scientist

Leadscope, Inc., US

Dr. Ir. Lise Vanderkelen

Dep. Head Pharma Services

Toxikon Europe nv, Belgium

Dr. David Snodin

Independent Consultant

Xiphora Biopharma Consulting, UK

Dr. Patrick Reichl

Sr. Scientific Professional

Shire, Austria

Annual

Events

Sponsors and Partners

Sponsor

Media partner

Media partner

Media partner

Media partner